Evidence map›Paper›PMID 37564252›Full record

ReviewJournal of clinical and translational research2023

Safety and efficacy of intranasal insulin in patients with Alzheimer's disease: a systematic review and meta-analysis.

Yosra Hussein AboEl-Azm, Mohamed El-Samahy, Nada Ibrahim Hendi, Amina Arar, Noha Samy Yasen, Shrouk Ramadan, Esraa M Zedan, Nada Mostafa Al-Dardery, Abdulrhman Khaity

Abstract readReview
In one paragraph

Review in Journal of clinical and translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Intranasal insulin for improving cognitive function in multiple sclerosis.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Trial
  2. Review
  3. Boosting Neurogenesis as a Strategy in Treating Alzheimer's Disease.International journal of molecular sciences · 2025
    Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yosra Hussein AboEl-AzmDepartment of Medicine, Faculty of Medicine, Zagazig University, Zagazig, 44519, Egypt.
Mohamed El-SamahyDepartment of Medicine, Faculty of Medicine, Zagazig University, Zagazig, 44519, Egypt.
Nada Ibrahim HendiDepartment of Medicine, Medical Research Group of Egypt, Cairo 44523, Egypt.
Amina ArarDepartment of Medicine, Medical Research Group of Egypt, Cairo 44523, Egypt.
Noha Samy YasenDepartment of Radiology, Faculty of Applied Medical Sciences, Misr University for Science and Technology, Cairo, 12566, Egypt.
Shrouk RamadanDepartment of Medicine, Medical Research Group of Egypt, Cairo 44523, Egypt.
Esraa M ZedanDepartment of Medicine, Medical Research Group of Egypt, Cairo 44523, Egypt.
Nada Mostafa Al-DarderyDepartment of Medicine, Medical Research Group of Egypt, Cairo 44523, Egypt.
Abdulrhman KhaityDepartment of Medicine, Medical Research Group of Egypt, Cairo 44523, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aim: We performed this meta-analysis to evaluate the safety and efficacy of intranasal insulin in Alzheimer's disease (AD) patients. Methods: A literature search was conducted for PubMed, Scopus, and Web of Science from inception until August 2022. Documents were screened for qualified articles, and all concerned outcomes were pooled as risk ratios or mean difference (MD) in the meta-analysis models using Review Manager (RevMan version 5.4). Results: Our results from 12 studies favored intranasal insulin over placebo in terms of Alzheimer Disease's Assessment Scale-cognitive subscale (ADAS-cog) 20 IU, (MD = -0.13, 95% CI [-0.22, -0.05], Conclusion: Ultimately, this meta-analysis showed that intranasal insulin in small doses (20 IU) significantly affects patients with AD. Further studies are recommended on reliable insulin delivery devices to increase insulin in the central nervous system. Relevance for Patients: Intranasal insulin has shown promising results in treating patients with AD. The lower doses (20 IU) can play a positive role in improving the disease. As research continues, it is likely that this treatment will become more widely accepted and utilized in clinical practice.

Indexed as

Alzheimer’s diseaseintranasal insulinmild cognitive impairment

Identifiers

PMID37564252
PMCPMC10411979

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.